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O-linked N-acetylglucosamine modification (O-GlcNAcylation)
is a nutrient-dependent protein post-translational modification
(PTM), dynamically and reversibly driven by two enzymes:
O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA)
that catalyse the addition and the removal of the O-
GlcNAc moieties to/from serine and threonine residues of
target proteins respectively. Increasing evidence suggests
involvement of O-GlcNAcylation in many biological processes,
including transcription, signalling, neuronal development and
mitochondrial function. The presence of a mitochondrial O-
GlcNAc proteome and a mitochondrial OGT (mOGT) isoform
has been reported. We explored the presence of mOGT in human
cell lines and mouse tissues. Surprisingly, analysis of genomic
sequences indicates that this isoform cannot be expressed in most
of the species analysed, except some primates. In addition, we
were not able to detect endogenous mOGT in a range of human
cell lines. Knockdown experiments and Western blot analysis of
all the predicted OGT isoforms suggested the expression of only
a single OGT isoform. In agreement with this, we demonstrate
that overexpression of the nucleocytoplasmic OGT (ncOGT)
isoform leads to increased O-GlcNAcylation of mitochondrial
proteins, suggesting that ncOGT is necessary and sufficient for
the generation of the O-GlcNAc mitochondrial proteome.
Key words: alternative splicing, glycobiology, mitochondria,
O-GlcNAc transferase (OGT), O-linked N-acetylglucosamine
(O-GlcNAc), post-translational modification (PTM).
INTRODUCTION
O-linked N-acetylglucosamine modification (O-GlcNAcylation)
is a dynamic post-translational modification (PTM), characterized
by the reversible covalent attachment of N-acetylglucosamine
on serine and threonine residues of target proteins [1–3]. Over
the last decade, its primary role in many biological processes
in eukaryotes has been established [4–8] although many of
the mechanisms underlying O-linked N-acetylglucosamine (O-
GlcNAc) function remain to be elucidated. Interestingly, many O-
GlcNAc proteins are also phosphorylated and evidence of a degree
of interplay between phosphorylation and O-GlcNAcylation
has been reported [7,9,10]. O-GlcNAc cycling is driven by
the concerted activity of two enzymes, O-GlcNAc transferase
(OGT) and O-GlcNAcase (OGA) that catalyse the attachment
and the removal of O-GlcNAc respectively [11–13]. Although
substrate specificity and regulatory mechanisms of OGT and
OGA remain largely elusive, they are essential for stem cell
viability and mouse embryonic development [14,15]. In addition,
impaired O-GlcNAc metabolism has been implicated in several
human diseases, such as diabetes mellitus and neurodegenerative
disorders [7,8,16–18]. O-GlcNAcylation is a nutrient-dependent
process and appears to be regulated by intracellular glucose
availability [19,20]. Approximately 2–5% of the intracellular
glucose is metabolized through the hexosamine biosynthetic
pathway, a metabolic process that utilizes one of the metabolites
from glycolysis to produce UDP-GlcNAc, which is the high
energy donor substrate of OGT [11,21]. Human OGT (hOGT) is
a 116 kDa enzyme containing a C-terminal catalytic domain and
12 N-terminal tetratricopeptide repeats (TPRs) that are known to
be involved in protein–protein interactions [22]. A single hOgt
gene has been mapped to the X chromosome at Xq13.1, a region
associated with Parkinson’s disease [23]. Four transcripts have
been reported to originate from the Ogt gene in human, rat
and mouse [24,25], possibly by alternative splicing or alternative
promoters. Western blots performed on HeLa cell lysates, using
affinity-purified rabbit polyclonal OGT antibodies, showed the
presence of two distinct bands. The 116 kDa band corresponds
to the nucleocytoplasmic OGT (ncOGT). An additional band,
migrating at approximately 103 kDa, has been proposed to be a
different splicing isoform [25]. Interestingly, the longest of the
putative Ogt transcripts (approximately 9.5 kb) is characterized
by a very long 5′-UTR, originating from the retention of intron 4
(also referred to as exon 5). This long RNA has been detected in
several human and mouse tissues by Northern blot. This region, in
the human gene, contains a predicted translation start site that, if
utilized, would code for an OGT lacking the first three TPRs
but possessing a unique 50 residue N-terminus, arising from
the retained intron. This putative protein, containing nine TPRs
and the catalytic domain, should result in a 103 kDa isoform
[25]. Prediction tools identify a non-canonical mitochondrial
targeting sequence (MTS) within the unique N-terminal region
of such protein [26]. This 103 kDa band is enriched in the
mitochondrial fraction in HeLa cells, and it has been referred to
as mitochondrial OGT (mOGT) [26]. This proposed isoform has
been shown to be active in vitro [27], whereas its overexpression
leads to apoptosis in some cell lines [28]. Catalytically inactive
GFP-tagged mOGT, overexpressed in HeLa cells, is targeted
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to mitochondria, whereas in the absence of the predicted
MTS, it is localized in the cytosol [26]. The biological role
of mOGT in human cell lines has not been investigated. It
has been suggested to be involved in O-GlcNAcylation of
mitochondrial proteins, apoptosis and/or metabolic pathways
[29]. Functional consequences of nuclear and cytoplasmic O-
GlcNAcylation have been extensively studied, whereas very
little is known about the mechanistic biology resulting from
mitochondrial protein O-GlcNAcylation. Initially, no O-GlcNAc
was detected in mitochondrial fractions by Western blot [26].
Nevertheless proteomics and more sensitive anti-O-GlcNAc
antibodies have overcome this issue. Notably, mitochondrial O-
GlcNAcylated proteins have been identified in mouse cardiac
myocytes, rat heart and rat liver by mass spectrometry (MS)
[30–33]. Moreover, the presence of OGT and OGA has
been detected by immunogold labelling in mitochondria [34].
Interestingly, increased mitochondrial protein O-GlcNAcylation,
due to hyperglycaemic conditions in cardiac myocytes, has
been associated with modulation of the electron transport chain
activity, oxygen consumption rate, ATP production and calcium
uptake [30,35]. Similarly, 2D electrophoresis experiments have
shown that mitochondrial protein O-GlcNAc modification and
phosphorylation patterns are altered in myoblasts exposed to
high glucose concentrations [36]. More recently, Tan et al.
[37] have demonstrated that overexpression of ncOGT or OGA
alters protein expression levels in mitochondria and severely
affects mitochondrial morphology and metabolic processes. O-
GlcNAcylation of dynamin-related protein 1 (Drp1), which is
one of the main regulators of mitochondrial dynamics, induces
mitochondrial fragmentation and altered membrane potential
in cardiac myocytes [38]. Another O-GlcNAcylated protein is
trafficking kinesin-binding protein 1 (TRAK1)/Milton, which
is known to form a stable complex with ncOGT and with the
kinesin mitochondrial transport machinery [39,40]. Increased O-
GlcNAcylation of TRAK1 in hyperglycaemic conditions leads
to altered mitochondrial axonal transport [41]. Finally, increased
O-GlcNAcylation in aging rat retina has been proposed to have
a protective effect on mitochondrial respiration and dynamics
as well as redox homoeostasis, helping prevent reactive oxygen
species (ROS)-related aging [42]. Together, these studies suggest a
potential and largely unexplored link between O-GlcNAc cycling
and many key biological functions carried out by mitochondria,
such as ATP production, lipid metabolism, apoptosis and ROS
homoeostasis, although it is not clear whether O-GlcNAc
directly regulates these processes [43]. Exploration of the role
of O-GlcNAc in mitochondrial physiology may uncover links
with mitochondrial dysfunction, dynamics and transport in
neurodegenerative, neuroinflammatory and autoimmune diseases
[44,45].
In this work, we probed the presence and role of the previously
reported mOGT isoform in cell lines and animal tissues. We
also studied the contribution of ncOGT and mOGT in generating
the mitochondrial O-GlcNAc proteome. Surprisingly, it appears
that ncOGT is sufficient for O-GlcNAcylation of mitochondrial
proteins, in agreement with mOGT being undetectable.
MATERIALS AND METHODS
Cloning and primers
The previously reported mOGT coding region [26] was
amplified by PCR (SuperScript III One-step RT PCR kit,
Invitrogen) from human cDNA using the following sets of
primers: 5′-aaaggatccatgctgcagggtcacttttggctgg-3′ and 5′-cgtc-
tcaattgctttcaaataacatgcc-3′ first, followed by 5′-cgagatccattgt-
gctggatctacaatgctgcagggtcacttttggc-3′ and 5′-cgtctcaattgctttcaa-
ataacatgcc-3′. The resulting PCR product was cloned in
a pEBG6P backbone according to published methods
[46] to generate a tagless construct. To add a C-terminal
FLAG-tag, the QuikChange site-directed mutagenesis kit
(Stratagene) was used with the following primers: 5′-gcctg-
ttgaagtcactgagtcagcagctgactacaaggacgatgacgataagtaagcggccgcg-
actctagagtgag-3′ and 5′-ctcactctagagtcgcggccgcttacttatcgtcatcgt-
ccttgtagtcagctgctgactcagtgacttcaacaggc-3′.
Cell culture and transfection
Human embryonic kidney (HEK) 293 and HeLa cells were
cultured in Dulbecco’s modified Eagle medium (DMEM) medium
(Gibco), supplemented with 10% FBS, L-glutamine, penicillin
and streptomycin, at 37 ◦C in a humidified 5% CO2 incubator.
HEK 293 suspension cells were grown in Pro 293s-CDM medium
(Lonza), supplemented with 1% FBS, L-glutamine, penicillin
and streptomycin, at 37 ◦C in a humidified 5% CO2 incubator
with gentle shaking. HEK 293 cells were plated on 10 cm dishes
at 50% confluence and then transfected for 48 h with 10 μg
of plasmid using 5 μg of polyethylenimine (PEI, Polyscience)
transfection reagent. HeLa cells were plated on 10 cm dishes at
90% confluence and then transfected for 24 h with 10 μg of
plasmid and 5 μl of Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s instructions. For HEK 293 suspension cell
transfection, 2 × 108 cells were grown for 4 h in 50 ml serum-
free medium in 250 ml flasks. A transfection mixture, containing
100 μg of DNA and 50 μg of PEI in 10 ml serum-free medium
was added to the cells and incubated at 37 ◦C for 4 h. Finally
1% FBS in 40 ml medium was added to the cells up to a final
volume of 100 ml and cells were incubated with gentle shaking at
37 ◦C for 72 h. For knockdown experiments, HeLa cells were
plated on six-well plates at 70% confluence and transfected
for 48 h and 96 h with 100 pmol ON-TARGETplus OGT set of
four siRNA (GE Dharmacon) using 2 μl of Lipofectamine 2000.
After 48 h, growth medium was changed and fresh transfection
mixture was added to increase silencing efficiency. For HeLa
cell mOGT transfection, in combination with siRNA, cells were
transfected at the same time with 100 pmol ON-TARGETplus
OGT set of four siRNA and 10 μg of mOGT construct, in the
presence of 5 μl Lipofectamine 2000. Cells were then incubated
for 48 h.
RNA extraction and PCR
Mouse tissues were obtained from adult female mice after
cervical dislocation. Total RNA was isolated from tissue
and from cultured human cell lines using the TRI-Reagent
(Sigma–Aldrich) according to the manufacturer’s instructions.
Ten micrograms of each RNA sample was digested with
DNAse (New England BioLabs) to eliminate genomic DNA
contamination. cDNA was prepared with the Precision nanoScript
reverse transcription kit (Primer Design), using 1 μg of starting
material. The following sets of primers were used to amplify
different regions of the Ogt gene in human and mouse
samples (Figure 2): (1) forward 5′-ctcaaagccctgggtcgctt-3′,
reverse 5′-gcaaagttcggttgcgtctc-3′; (2) forward 5′-gccatacctc-
ttaacacctc-3′, reverse 5′-gcaaagttcggttgcgtctc-3′; (3) forward
5′-ccctgggtcgcttggaagaa-3′, reverse 5′-ggatgaaattcttctccact-3′;
(4) forward 5′-ttctgatgatgcgctgtgac-3′, reverse 5′-aggctcgcttg-
cgccaaa-3′. PCR products were analysed on 1% agarose gel
containing GelRed fluorescent staining (Biotium).
Purification of mitochondria and protease protection assay
Mitochondria were purified from mouse liver and HEK 293
suspension cells as described previously [47] with minor
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modifications. Unless specified, all steps were carried out at
4 ◦C. Briefly, 4 × 108 cells were washed in ice-cold PBS,
pH 7.5, resuspended in 10 ml of mitochondria isolation buffer
(MIB: 10 mM Tris/MOPS, pH 7.4, 1 mM EGTA/Tris, 200 mM
sucrose) and disrupted with a Glass-Teflon homogenizer (Thomas
Scientific, 20–25 passes). Mouse liver was quickly extracted
from female mice after cervical dislocation, washed four times
in 50 ml of ice-cold MIB and minced in small pieces with
scissors. The tissue was then resuspended in 10 ml of MIB
and homogenized (25–30 passes). Cell or liver homogenates
were spun at 600 g for 10 min. Pellets, containing nuclei
and unbroken cells, were collected for SDS/PAGE, whereas
supernatants were spun again at 600 g for 10 min to remove
cell debris and remaining nuclei. Supernatants were transferred
into 30 ml round-bottomed glass centrifuge tubes and spun at
7000 g for 10 min. After centrifugation, supernatants, mainly
containing the cytosolic fraction, were collected for further
analysis. Pellets, mainly containing the mitochondrial fraction,
were resuspended in 10 ml of MIB and spun again at 7000 g for
10 min to remove cytosolic contaminants. Mitochondria-enriched
pellets were then collected and used for subsequent experiments.
Protease protection experiments were performed as described
elsewhere [48,49]. Briefly, freshly isolated mitochondria were
resuspended in MIB containing 10 μg/ml proteinase K (Sigma–
Aldrich) and incubated on ice for 30 min with gentle mixing every
5 min. Proteolysis was terminated by adding 5 mM PMSF and
Laemmli sample buffer and by heating the samples at 95 ◦C for
10 min.
Cell lysis and immunoprecipitation
Cell or tissue samples were washed in ice-cold PBS, homogenized
in a glass homogenizer where necessary, and incubated for
10–30 min in lysis buffer (50 mM Tris/HCl, 1 mM EGTA,
1 mM EDTA, 1% Triton X100, 1 mM sodium orthovanadate,
50 mM NaF, 5 mM sodium pyrophosphate, 0.27 M sucrose,
0.1% 2-mercaptoethanol and CompleteTM protease inhibitor
cocktail containing 1 mM benzamidine, 0.2 mM PMSF and 5 μM
leupeptin) on ice. Lysates were spun at 15000 g for 10 min
at 4 ◦C. Supernatants were collected for immunoprecipitation
experiments or diluted in Laemmli sample buffer containing
5% 2-mercaptoethanol for SDS/PAGE. Immunoprecipitation
experiments were carried out by incubating cell/tissue lysates
(between 0.5–4 mg) with OGT antibody (DM-17, Sigma–
Aldrich) at 4 ◦C with gentle rolling overnight. Subsequently,
protein-G Dynabeads (Life Technologies) were added to the
lysate for 2 h at 4 ◦C with gentle rolling. Dynabeads were then
washed thrice with 1 ml of washing buffer (20 mM Tris/HCl,
pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.05% Triton X100, 5%
glycerol and CompleteTM protease inhibitor cocktail). Finally,
beads were incubated with Laemmli sample buffer containing
5% 2-mercaptoethanol and heated at 95 ◦C for 10 min to elute
proteins.
SDS/PAGE and Western blot analysis
For Western blot analysis, protein samples were separated
by SDS/PAGE and transferred on to nitrocellulose membrane
(Whatman). The membranes were blocked for 1 h in 5% non-
fat milk powder or 5% BSA in TBS-0.2% Tween20 (TBS-T)
buffer for 1 h at room temperature with gentle shaking. Then,
the following primary antibodies, diluted in blocking buffer, were
added to the membranes overnight at 4 ◦C: anti-OGT (DM-17,
Sigma–Aldrich), anti-OGT (Abcam ab177941), anti-O-GlcNAc
(RL2, Abcam), anti-O-GlcNAc [C-terminal domain (CTD) 110.6,
Cell Signaling], anti-TOM20 (F-10, Santa Cruz Biotechnology),
anti-ATP synthase β subunit (ATPB, 3D5, Abcam), anti-
Timm13 (A01, Abnova), anti-HSP60 (D307, Cell Signaling),
anti-α-tubulin (12G10, Developmental Studies Hybridoma Bank,
University of Iowa) and anti-α-tubulin (11H10, Cell Signaling).
The following fluorescent secondary antibodies, diluted in 1%
milk in TBS-T, were added to the membranes for 1 h at room
temperature: donkey anti-rabbit 800, donkey anti-mouse 680,
goat anti-rabbit 800 and goat anti-mouse 680 (LI-COR). Images
were acquired and analysed using the LI-COR Odyssey Image
System.
RESULTS
The mOGT ORF is not conserved in mammals
The conservation and presence of mOGT across the mammalian
kingdom has not been studied. To predict the presence of mOGT
protein, sequence alignment of the genomic region coding for
the putative human mOGT ORF and the Ogt gene in other
species was performed. The mOGT translation start site of the
human gene lies within intron 4 (also referred to as exon 5),
150 bp from the intron/exon boundary (Figure 1). This region
shows high homology among all the species analysed (Table 1).
Surprisingly, when the homologous sequences were analysed
using the ExPAsy translate tool to predict ORFs, a shift in the
reading frame was observed, leading to the introduction of a
premature stop codon, in mouse as well as most of the other
species analysed (Figure 1 and Table 1). This appears to exclude
the possibility of a functional mOGT protein being translated
from an ORF through a mechanism similar to that in human. Only
some primates, cow and goat contain a putative ORF, although the
presence of mOGT in these organisms has never been investigated
at the protein level. We also analysed sequence similarity in
lower organisms including Drosophila, Caenorhabditis elegans
and zebrafish, but in these cases no significant homology of
intron 4 was detected. The reading frame shift was confirmed in
mouse liver genomic DNA by sequencing PCR products. Hence,
a more detailed investigation on the retention of intron 4/exon
5 in human and mouse was carried out. For this purpose, reverse
transcriptase PCRs to detect the transcript carrying intron 4/exon 5
were performed on mRNA from HEK 293 cells and mouse tissues,
using four primer combinations (Figure 2A). Results from this
experiment demonstrate that the transcript carrying intron 4/exon
5 is present both in mouse and human (Figures 2B and 2C).
Endogenous mOGT protein is not detectable
mOGT was previously identified by Western blot in HeLa cells,
although its presence in other human cell lines or tissues has
not been explored [26]. We probed lysates from several cultured
human cell lines with a commercial OGT antibody (Sigma clone
DM-17) to assess mOGT expression levels. This antibody was
raised against a synthetic peptide corresponding to amino acids
740–756 of the C-terminus of ncOGT and it should detect all
of the predicted OGT isoforms. In agreement with published
data, ncOGT can be clearly detected on Western blot, with
varying expression levels in different cell lines and conditions
(Figure 3). To confirm that the DM-17 anti-OGT antibody can
indeed detect mOGT, lysates from HEK 293 cells, transfected
with a tagless mOGT construct, were analysed by Western blot
(Figure 3A). Results show that the DM-17 antibody is able to
detect overexpressed mOGT. An additional band, at a molecular
mass (103 kDa) compatible with mOGT, was also detected
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Figure 1 Conservation of mOGT
The 150 bp region between the predicted mOGT start site within intron 4/exon 5 and exon 6 in the hOgt gene was aligned with the homologous region in other species. Example of alignment between
the human, goat and mouse sequences is shown. The green boxes indicate the putative mOGT start codon. The red box in the mouse sequence highlights the stop codon.
(Figure 3B). Lysates from different mouse tissues were also
probed with DM-17 antibody (Figure 3C). The 103 kDa mOGT
band is not detected in the mouse tissues analysed, but several
non-specific bands appeared with high exposures. An attempt
at generating an mOGT-specific antibody using the predicted
unique N-terminus as antigen was unsuccessful. Localization of
the putative mOGT in human cell lines was investigated. Total cell
and mitochondrial lysates from HEK 293 cells were subjected to
OGT DM-17 Western blot analysis (Figure 4). Two distinct bands
can be observed in total lysates, supposedly corresponding to
ncOGT and mOGT, but neither of these two bands is distinctly
enriched in the mitochondrial fraction. Although weak bands are
detectable in mitochondria, this could be due to contamination
from other cell compartments.
To ascertain the specificity of the putative 103 kDa mOGT
band, knockdown of OGT was attempted using OGT siRNA.
A combination of four siRNAs covering the whole Ogt gene
sequence was used in HeLa cells for 48 h and 96 h. These should
theoretically knockdown any predicted OGT isoform. Western
blot analysis showed a strong reduction in global O-GlcNAc
levels, in particular with 96 h siRNA transfection (Figures 5A and
5B). Similarly, ncOGT expression was reduced by approximately
70% upon knockdown. Surprisingly, the 103 kDa putative mOGT
band was not affected by the treatment (Figures 5A and 5B).
The ability of the siRNA to knockdown the putative mOGT
transcript was tested by overexpressing mOGT. Overexpressed
mOGT protein levels were significantly reduced upon OGT
siRNA treatment, demonstrating that the mOGT transcript is
susceptible to knockdown with these reagents (Figure 5C). These
data suggest that the endogenous putative mOGT immunogen may
be a non-specific band detected by the DM-17 OGT antibody. To
Table 1 Bioinformatic analysis of predicted presence of mOGT ORFs
Species Sequence identity Gaps mOGT ORF
Gorilla gorilla (gorilla) 100% 0/150 Yes
Pongo pygmaeus (orangutan) 100% 0/150 Yes
Macaca mulatta (macaque) 99% 1/150 No
Callithrix jacchus (marmoset) 97% 4/150 No
Capra hircus (goat) 95% 3/150 Yes
Sus scrofa (pig) 95% 5/150 No
Canis familiaris (dog) 95% 5/150 No
Ovis aries (sheep) 95% 5/150 No
Felis catus (cat) 94% 3/150 No
Equus caballus (horse) 94% 6/150 No
Bos taurus (cow) 93% 9/150 Yes
Oryctolagus cuniculus (rabbit) 93% 3/150 No
Rattus norvegicus (rat) 90% 6/150 No
further dissect this, another commercial OGT antibody (Abcam),
also raised against a portion of the catalytic domain (between
amino acid 1000 and the C-terminus of ncOGT), was used.
Both antibodies are able to detect ncOGT both in human and
in mouse tissue total lysates but no specific band is detected in
mitochondrial fractions (Figure 5D). A relatively faint 103 kDa
band, detected by the DM-17 antibody in total lysates, is
not reactive to the Abcam antibody, even at higher exposure.
Given that both antibodies can detect overexpressed mOGT,
this suggests that the 103 kDa band may not correspond to
mOGT. Endogenous ncOGT but not the 103 kDa band, could
be immunoprecipitated from total HEK 293 lysate or the mito-
chondrial fraction with the DM-17 antibody (Figures 5E and 5F).
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Figure 2 Analysis of mOGT-coding transcripts in human cell lines and mouse tissues
(A) PCR was performed on cDNA prepared from human HEK 293 cells and mouse tissues. Different primer combinations, specific for the human and the murine Ogt sequence, allowed detection
of the retained intronic sequence. Sizes of expected PCR products are also indicated. Amplified DNA samples from human (B) and mouse (C) were analysed on agarose fluorescent gel. An mRNA
sample not subjected to reverse transcriptase PCR (-RT) is included as a negative control. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a normalizing control.
This precluded identification of the 103 kDa band by MS or
N-terminal sequencing.
ncOGT is sufficient for O-GlcNAcylation of mitochondrial proteins
Given the apparent presence of only a single detectable OGT
isoform, it is worth exploring whether this isoform is sufficient
for generating the mitochondrial O-GlcNAc proteome. GFP-
tagged ncOGT was overexpressed in HEK 293 suspension cells.
Mitochondria were purified from cells and incubated with either
buffer or buffer containing proteinase K to digest the outer
membrane-associated proteins and contaminants. Overexpression
of ncOGT leads to increased O-GlcNAc in the mitochondrial
fraction (Figure 6B) and the same increase is visible in
the protease-treated sample, demonstrating that overexpressed
ncOGT is able to transfer O-GlcNAc on to mitochondrial proteins.
Interestingly, a trace of ncOGT is still visible in the mitochondrial
fraction after protease treatment, suggesting that part of ncOGT
itself might be imported into mitochondria and be involved in
O-GlcNAc cycling inside the organelle.
DISCUSSION
After the first report describing mOGT in 2003 [26], there have
been no further reports on this isoform for more than a decade,
whereas numerous studies have begun to uncover the functions
of ncOGT. Recent and previous proteomics data have revealed
the presence of O-GlcNAc modified mitochondrial proteins
[30,32,35]. Moreover, accumulating evidence suggests that O-
GlcNAcylation is an important regulator of many biological
processes related to mitochondrial function [8]. For instance,
O-GlcNAc appears to be important for mitochondrial function
and dynamics, by mechanisms not clearly understood [30,34,37].
However, it is still unclear whether and how much O-GlcNAc
directly affects mitochondrial metabolism [43]. The possible
functional link between O-GlcNAc and mitochondrial function
served as a starting point of this work, where we planned to
explore the role of mOGT in human and mouse and to investigate
how mOGT generates the mitochondrial O-GlcNAc proteome.
However, sequence alignments of intron 4/exon 5 in the predicted
hOGT ORF with the homologous region in other species revealed
the presence of a stop codon in most of the species analysed,
except some primates, goat and cow (Figure 1 and Table 1).
Human and mouse transcripts, retaining the putative mOGT N-
terminus, were detected (Figure 2). Data shown in this work are
in agreement with previous Northern blot experiments [24,25]
showing the existence of several transcripts derived from the
Ogt gene in various human and mouse samples. The presence
of many transcripts was also documented in zebrafish [50], where
different splice variants are differentially expressed at mRNA
level throughout development. Intron retention is a quite common
event and long untranslated RNAs were reported elsewhere [51].
Therefore, it is possible that some of the Ogt transcripts observed
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Figure 3 Detection of endogenous mOGT
(A) Varying amounts (1–5 μg) of a tagless mOGT construct were overexpressed in HEK 293 cells and lysates were probed with anti-O-GlcNAc (RL2), anti-OGT (DM-17) and anti-GAPDH antibodies.
(B) Expression of endogenous mOGT was assessed in different cell lines: HEK 293 suspension IL1R, HEK 293, Jurkat, SH-SY5Y, RAW, HeLa, U2OS and A549. Lysates were probed with anti-O-GlcNAc
(RL2), anti-OGT (DM-17) and anti-GAPDH antibodies. (C) Mouse tissue lysates were probed with the same antibodies.
have functions other than protein coding. The genomic alignments
shown in this work suggest that there is no mOGT ORF in the
mouse, precluding it as an animal model to study the function
of mOGT. The lack of mOGT in most species might suggest
that its function is not essential or that there is redundancy
between ncOGT and mOGT. The next step was to investigate the
presence and biological role of mOGT in human cell lines. This
isoform was previously detected using a non-commercial (and
unavailable) rabbit affinity-purified antibody [25,26]. We have
made several attempts to identify mOGT in human cell lysates
and mitochondrial fractions. Only one of the two commercial
antibodies tested was able to detect a band at the right molecular
mass, although results were inconsistent and variable (Figure 3).
Overexpressed mOGT, however, was readily detected by either
antibody used (Figures 3A and 5D). To further determine the
specificity of the antibodies, siRNA was performed in HeLa
cells, using a combination of four RNAs specific for both ncOGT
and mOGT. Results showed that only ncOGT protein levels
Figure 4 Putative mOGT is not enriched in mitochondrial fractions
Subcellular fractionation was performed in HEK 293 cells: nuclear, cytosolic and mitochondrial
fractions were analysed by Western blot.
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Figure 5 The 103 kDa band is not mOGT
(A) OGT siRNA was performed in HeLa cells for 48 h and 96 h. Lysates were analysed by Western blot. (B) Densitometry analysis of the blots shown in (A). (C) A combination of siRNA and mOGT
overexpression was also used to test the specificity of the siRNA. (D) Different lysates (HEK 293 total lysate, HEK 293 with mOGT overexpression, HEK 293 mitochondrial fraction, HeLa total lysate,
HeLa with OGT siRNA, HeLa with mOGT overexpression, mouse brain total lysate, mouse liver mitochondrial fraction) were probed with two different OGT commercial antibodies (DM-17 Sigma and
ab177941 Abcam). ATPB and α-tubulin served as mitochondrial and cytoplasmic marker respectively. OGT was immunoprecipitated from different untransfected HEK 293 lysates: total cell lysate (E)
or HEK 293 mitochondrial fraction (F). Anti-OGT antibody (DM-17) was used for immunoprecipitation.
were reduced, whereas the putative mOGT band, as well
as other non-specific bands, was not affected (Figures 5A
and 5B). The presence of additional non-specific bands was
previously reported using in-house developed rabbit antisera [11]
or other commercially available anti-OGT antibodies [52]. These
data suggest that the putative mOGT band detected with DM-17
antibody might be non-specific. The same band is not enriched
in HEK 293 mitochondrial fraction (Figure 4). In summary,
we could not detect mOGT protein under the experimental
conditions we used. It cannot be excluded that this particular
OGT isoform is expressed only transiently under very specific
conditions that are yet to be established.
Given the apparent absence of mOGT, we then explored
whether ncOGT itself may produce the mitochondrial O-GlcNAc
proteome. We showed that overexpressed GFP-tagged ncOGT is
able to increase O-GlcNAc on mitochondrial proteins (Figure 6).
Protease treatment of mitochondria from transfected cells
excludes the possibility that the increase in the O-GlcNAc levels
we observe is due to contaminants or outer membrane-associated
proteins. The idea of ncOGT being solely responsible for O-
GlcNAcylation of mitochondrial proteins is also supported by the
presence of mitochondrial O-GlcNAcylated proteins in mouse
and rat, where the mOGT protein is not present.
On the basis of the data presented here, we propose two
possible models. In the first, ncOGT and OGA respectively
add and remove O-GlcNAc from mitochondrial proteins in
the cytosol prior to import into mitochondria. In the second,
the two O-GlcNAc cycling enzymes are imported into the
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Figure 6 ncOGT is sufficient for O-GlcNAcylation of mitochondrial proteins
(A) HEK 293 suspension cells were transfected with either GFP or GFP-tagged ncOGT. Mitochondria, purified from transfected cells, were incubated with buffer or with 10 μg/ml of proteinase K.
Lysates from the mitochondrial or the cytosolic fractions were probed with anti-OGT, anti-α-tubulin (cytosol), anti-ATPB (mitochondrial matrix) and anti-TOM20 (mitochondrial outer membrane)
antibodies. (B) O-GlcNAc levels in mitochondrial fractions were detected with anti-O-GlcNAc antibody (CTD 110.6). The amount of protein loaded in each lane in (A) is 10 μg, whereas approximately
100 μg was used in (B).
organelle and perform their catalytic activity within mitochondria.
Most of the mitochondrial proteome is encoded by the nuclear
genome, translated in the cytosol and then transported into
mitochondria. This observation may support the first scenario.
Nevertheless, Figure 6(A) shows the presence of residual ncOGT
in mitochondrial fractions upon protease treatment, suggesting
that a portion of ncOGT is imported into the organelle. Recent
immunogold labelling experiments have shown the presence
of OGT and OGA in mitochondria [34]. Interestingly, the
pyrimidine nucleotide carrier 1 (pnc1) has been shown to be
responsible for transport of UDP-GlcNAc into mitochondria [34].
Knockdown of this transporter led to decreased mitochondrial
O-GlcNAcylation [34], suggesting the possibility of O-GlcNAc
cycling occurring within the organelle. This second scenario
is supported by immunoprecipitation experiments detecting O-
GlcNAc on cytochrome c oxydase I (COX I) [30] and a proteomic
screen mapping an O-GlcNAc site on NADH-ubiquinone
oxidoreductase chain 4 (mt-ND4) [35]. Both proteins are encoded
by the mitochondrial DNA and belong to the electron transport
chain. Therefore, they are never exposed to the cytoplasm and
would thus need to be modified in the mitochondrial matrix. It is
possible that both models are valid and different mitochondrial
substrates are reversibly O-GlcNAcylated either in the cytosol or
in the matrix/inner membrane. Other PTMs have been reported
in mitochondria, including phosphorylation and acetylation [53],
although it is not clear whether the modification takes place in the
cytosol before protein import or if the enzymes responsible for
these processes are also present inside mitochondria.
Taken together, the data shown in this work suggest that
ncOGT is the main isoform responsible for the generation of the
mitochondrial O-GlcNAc proteome. However, it is not possible
to exclude the presence of additional OGT isoforms encoded by
a different gene or another type of mitochondrial OGT. Further
studies are necessary to identify O-GlcNAcylated mitochondrial
proteins in human and to investigate the biological role of
O-GlcNAc on specific proteins in the context of mitochondrial
dysfunction and disease.
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